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In this study,  the  capacity of  normal  and neoplas- 
tic B lymphocytes to release  interleukin 1  (IL 1) has 
been  investigated.  Peripheral  blood B cells from  nor- 
mal donors were isolated by depletion of E rosetting 
cells and by positive selection of cells expressing 
surface  immunoglobulin (sIg) or the B1 marker.  Pe- 
ripheral blood B cells from patients with B cell 
chronic  lymphocytic  leukemia (B-CLL) were  purified 
by  removal of E rosetting cells followed  by  comple- 
ment-mediated cytotoxicity with selected mono- 
clonal  antibodies. All  of the  normal B cell  suspen- 
sions and the large  majority  of  the B-CLL cells pro- 
duced  in  culture  high  amounts  of IL 1 in  the 
absence of any  apparent  stimulus. Control experi- 
ments  ruled  out  that  small  numbers of monocytes 
in  the B cell  suspensions  could  represent  the  source 
of IL 1. These  data  support  the  contention  that B 
cells participate to the immune response as acces- 
sory cells for T cell  activation  not  only by physically 
presenting  antigen,  but also by releasing IL 1. 
In recent years, numerous studies have shown that 
lymphocytes produce soluble mediators  generally  called 
lymphokines (1  -5). Some of these, for  example interleu- 
kin 2 (IL 2), deliver signals to  lymphocytes and sustain 
their  proliferation (6). Others, such as interferon-?, acti- 
vate and potentiate effector mechanisms of immunity (7). 
Subpopulation studies have demonstrated that both T 
cells (1-6) and natural killer (NK) cells (8-14) produce 
lymphokines whereas little is known about the capacity 
of B cells to release these factors. Lack  of information  in 
this regard  may  be attributed  to the widespread  concept 
that the sole B cell function is that of producing specific 
antibodies. Consequently, most studies have been ad- 
dressed  to the process of B cell maturation,  both at the 
cellular (1 5) and at the molecular (16) level. More recently, 
however, it has been shown that B lymphocytes can 
function as antigen-presenting cells for T lymphocytes 
(1  7-25) and consequently subserve an accessory role  for 
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the induction of immune response. 
In this study, we have investigated  whether or not B 
cells release interleukin 1 (IL l ) ,  a cytokine  that  appears 
to play an important role in the early steps of T cell 
activation and in the control of the inflammatory re- 
sponse (as reviewed in Reference 26). We demonstrate 
that peripheral  blood B cells from  normal  individuals and 
from patients with B cell chronic  lymphocytic  leukemia 
(B-CLL)3 are effective producers of IL 1 .  
MATERIALS AND METHODS 
Cell fractlonation procedures. Peripheral blood mononuclear 
cells (MNC) from normal donors were separated on Ficoll-Hypaque 
(F-H) density  gradients. Monocytes were  partially removed by adher- 
ence.  T  cells  were removed from the  suspensions by rosetting  with 
neuraminidase-treated  sheep  erythrocytes (9). Cells expressing sur- 
face immunoglobulin (sIg) were isolated by rosetting  non-T  cells with 
ox erythrocyte coated with rabbit F(ab')a anti-human Ig serum  (27). 
Cells expressing  the B1 marker were purified by an indirect  rosetting 
technique. Briefly. non-T cell fractions were treated with OKMl 
monoclonal antibody  (Ortho Diagnostic Systems, Milano, Italy) and 
complement as reported  (1 3).  These  non-T cells (3 X lo7) were treated 
with 100 pl  of the B1 monoclonal (Coulter-Kontron. Milano, Italy) 
and were rosetted with 2 ml of 5% ox erythrocytes coated with a 
purified rabbit  anti-mouse lg antibody (27). After a 30-min  incuba- 
tion at  4°C. rosetting  cells (B1+ cells)  were separated from nonroset- 
ting  cells (Bl- cells)  on F-H density gradients. In some experiments, 
monocytes were recovered from plastic after  adherence by a rubbrr 
policeman. 
Cells from 12 B-CLL patients were also studied. The diagnosis of 
B-CLL was established by clinic, morphologic, and immunologic 
criteria. All of the patients had 25,000 white blood cells/mm3 or 
more (90% lymphocytes). B-CLL MNC suspensions were depleted of 
E rosettes as  above and  treated with the OKMl and Leu-7 mono- 
clonal antibodies  and complement (13). In some experiments, B-CLL 
B  cells  were  purified as B1+ cell; by using  the  technique described 
above. 
erythrocytes or sIg were detected as reported (1 3). The  murine mon- 
Cell surface marker analysis. Cells with receptors for sheep 
oclonal antibodies  used in  this  study were the  pan-T reagent OKT3 
(Ortho Diagnostic System): the B cell-specific antibody B1; the large 
granular lymphocytes (LGL)-specific reagents Leu-7 and Leu-1 l b  
ocyte-macrophage monoclonal. which also  stains LGL. OKMl; and 
(Becton Diekinson Laboratory System, Milano, Italy): the  anti-mon- 
the anti-HLA-DR monoclonal PTF 29/12  (28)  that  was kindly do- 
nated by Dr. G. Damiani. All of the above reagents were used in 
indirect  immunofluorescence with a  fluoroscein  isothiocyanate 
(F1TC)-conjugated rabbit F(ab'), anti-mouse Ig. Preparations were 
observed with a Leitz Orthoplan  fluorescence microscope. The per- 
cent of positive cells was calculated  on at  least 200 cells per prepa- 
the cytochemical localization of a-naphthyl  acetate  esterase (ANAE) 
ration. In some experiments, cell suspensions were also  stained for 
as reported (9). 
herent cells were cultured (1 X 106/ml) for 48 hr in RPMI 1640 
Preparation of culture  supernatants. B1+ cells or recovered ad- 
supplemented  with 10% fetal calf serum (FCS) (Flow Laboratories, 
Milano, Italy) in 24 macro-well plates (Flow). Supernatants were 
harvested after centrifugation and were  stored at -20°C. 
3Abbreviations used in this paper: slg, surface immunoglobulin: B- 
CLL. B cell chronic lymphocytic leukemia; MNC. mononuclear  cells. 
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IL 1 QSSUIJ. IL 1  activity was  assayed by the conventional  thymo- 
cyte assay  (29). In brief, thymocytes  from C3H/HeJ mice were cul- 
tured for 72 hr in 96-well flat bottomed plates (Flow) at   the concen- 
tration of 1.5 x 106/well in the presence of phytohemagglutinin 
(PHA:  Difco. Detroit, MI) (1 rl/ml) alone. or of PHA plus  serial dilu- 
tions of the  supernatant  to be tested. At the  end of this time,  cells 
were pulsed with 1 pCi of 13H]thymidine for 8 hr. were harvested. 
and were counted. One unit of IL 1 was defined as the  amount of 
supernatant  capable of doubling the [3Hlthymidine uptake by 1.5 X 
1 O6 PHA-stimulated thymocytes. 
Because the  presence of IL 2 in test  supernatant could interfere 
with the  results of the IL 1 assay. IL 2 activity was  measured  in all 
of the conditioned  media as reported (14). Briefly. the  capacity of the 
normal T cell line that had been expanded  and kept in  culture for  2 
following cells to be stimulated was determined: a PHA-induced 
mo by adding exogenous IL 2: this  line  was  unresponsive  to PHA in 
the  absence of any  irradiated accessory cell: and  the  murine cell line 
CTLL-2.  Both assays  consistently failed to  detect  any IL 2  activity in 
B cell or monocyte supernatants. 
Molecular  weight  deterrninatlon of IL 1 .  To 80 ml of normal B 
cell or monocyte culture  supernatants (NH&S04 was added to a final 
concentration of 75%.  The precipitate was centrifuged, was  resus- 
pended  in phosphate-buffered  saline  containing 50 pglml gentami- 
cin (PBS). and  was dialyzed extensively against the same buffer. 
Aliquots of 3 ml were then gel filtered on a Sephadex G-75 Superfine 
(Pharmacia) column  equilibrated with PBS and were  calibrated  with 
the following markers: aldolase (158,000 m.w.), human  serum al- 
bumin (69,000 m.w.). isolated Ig light chains (23,000 m.w.), and 
cytochrome  c (12,300 m.w.). A flow rate of 10 ml/hr  was used, and 
2-ml fractions were collected. Aliquots of the  fractions were 0.22 pm 
filtered and were assayed  for IL 1 activity as described above. 
RESULTS 
In initial  studies,  normal B cells were isolated from the 
non-T cell fraction of peripheral blood by rosetting  with 
ox erythrocytes coated with anti-Ig antibodies  (Table I). 
sIg' cells produced large amounts of IL 1 (Table 11), but 
monocyte contamination of these cell populations was 
TABLE I 
Surface  phenotype of normal and  B-CLL-enriched  B  cell susoenslons 
Surface Marker 
Percent of Positive  Cells" 
sIg+ cellsb B1+ cells' B-CLL B cellsd 
sk2 92 C 5' 9 5 + 4  
B1 80 C 6 96 ? 3' 95 * 3 N.D/ 
HLA-DR 95 C 3 98 + 2 98 f 5 
OKT3 < I  C1 
OKM 1 15?3 C2 
Leu- 1 1 
Leu-7 
4 + 1  Cl 
2 C 0.3 <1 
< I  
<1 
<2 
< 1  
~~ 
the square root of the pooled variance divided by the overall number of 
a Mean t SE from three different experlments. The SE is calculated as  
samples. The  homogeneity of variance between experiments was dem- 
onstrated. and no significant difference between the means was docu- 
mented. 
sIg (see Materiak  and  Methods). 
B cells  were  isolated by direct rosetting according to the expression of 
of B1 antigen (see Materials  and  Methods). 
B cells were  isolated by indirect rosetting according  to the expression 
by treatment with OKMl and Leu-7  monoclonal antibcdles plus comple- 
B-CLL B cells were obtained by depletion of E rosetting cells followed 
ment. 
e Detected by rosetting during the separation procedures. 
'Not done because of the low-density expression of slg by  B-CLL B cells. 
TABLE I1 
IL 1 production by cell suspensions  enrichedfor  B  cells  and 
monocytes 
IL 1 Actlvl tp  
Supernatants from (U/mil 
EXDt. 1 Exot. 2 Exot. 3 
~~ ~ 
sIg' cells 130 116 110 
B1+ cells 129 118 98 
Autologous  mon cytesb 78  84 79 
"Supernatants were tested at different dilutions. and the reported 
values are relative to those yielding the highest activity. IL 1 produced by 
1 x 10' cells cultured for 48 hr. 
Monocytes  were  recovered  from plastic after adherence, 
too high to  indicate conclusively that B cells could be the 
source for the detectable cytokine (Table I). 
To overcome these difficulties, the following purifica- 
tion procedure was used: peripheral blood non-T cells 
partially depleted of monocytes by adherence  to  plastic 
were treated  with OKMl antibody and complement. The 
remaining cells were subsequently  fractionated  into B1+ 
and B1- cells by an  indirect  rosetting  technique.  The B1+ 
cell suspensions contained 95% or more B cells (as de- 
tected by staining for sIg), thus being considerably less 
contaminated than  the sIg+ cell preparations (Table I]. 
The reasons for the improved B cell purification are 
depletion of  OKM 1+ monocytes by complement-mediated 
cytotoxicity and  failure of the B1 monoclonal antibody to 
bind to monocytes, as opposed to the anti-Ig reagent, 
which  consistently reacted with sIg molecules passively 
absorbed  on  a proportion of monocytes. The  capacity of 
B1+ cells to produce IL 1  was  tested and  was compared 
with that of autologous monocytes recovered after  adher- 
ence  to  plastic  surfaces  (Table 11). These  adherent cells 
contained 90% k 5% monocytes, as determined by reac- 
tivity with the OKMl monoclonal antibody and by the 
characteristic  pattern of ANAE staining. Minor contam- 
inants were  represented by B cells (4%), T cells (2%), and 
LGL (2%). B1+ cells released IL 1 in quantities that, on  a 
per cell basis, were comparable with, or higher than, 
those produced by monocytes (Table 11). This finding 
makes it unlikely that  the few monocytes present  in the 
B1+  cell suspensions were responsible  for IL 1 production. 
The possibility that B cells released IL 1 as a  consequence 
of endotoxin stimulation was ruled out by the observation 
that  the batch of FCS used had a very low endotoxin 
content, as assessed by the Limulus assay.  Furthermore, 
B cells cultured in medium containing 1 % human  serum 
albumin  in  the place of FCS retained the ability to pro- 
duce IL 1. 
B cells from  12 B-CLL patients were also  tested for IL 
1 release (Table 111). B cells were isolated from peripheral 
blood MNC by removing E rosettes and subsequently 
treating  the  suspensions with the OKMl and Leu-7 mon- 
oclonal antibodies and complement. The  last  treatment 
was  necessary,  because these  suspensions  still  contained 
4% f 1 OKMl+ and 3% -+ 1 Leu-7+ cells. After this 
procedure, the  suspensions were enriched for B cells up 
to 95% or  greater (Table I). In some cases, B cells were 
purified by enrichment for B1+ cells by using rosette 
methods, and  results were virtually identical. Nine of the 
12 cases studied (75%) produced IL 1 in amounts that 
TABLE 111 

























"Supernatants were tested at different dilutions. and the reported 
values are relative to those yielding the highest activity. IL 1 produced by 
1 X 10' cells cultured for 48 hr. 
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were comparable  with  those of normal  B cells (Table 111). 
Interestingly,  neither  normal nor malignant  B cells re- 
leased IL 2, measured by the  support of IL 2-dependent T 
cell growth. Thus,  the IL 1 activity detected by the thy- 
mocyte assay could not be due to the presence of IL 2 
(data not shown). Normal B cell supernatants were am- 
monium sulphate precipitated and were subsequently gel 
filtered over a Sephadex G75 column. Figure 1 shows  the 
elution pattern of the B cell-derived factor with IL 1 
activity, which is superimposable to that released by 
normal monocytes. A s  evident, the  apparent m.w. of both 
molecules is in  the  range between 15,000  and 20,000. 
DISCUSSION 
Our  study  demonstrates  that  peripheral blood B cells 
from both normal  donors and B-CLL patients produce IL 
1. Normal and  malignant B cells apparently released IL 1 
constitutively  in the absence of any stimulation. On the 
basis of m.w. determination  (15.000 to 20,000). the avail- 
able data suggest that  this factor could be similar to that 
released by monocytes. The possibility exists  that cells 
were induced to  release IL 1 by contact with FCS or even 
plastic tissue  culture  ware. Alternatively, IL 1 may have 
been produced by B cells preactivated in vivo (30). While 
this  manuscript  was  in  preparation,  Matsushima et al. 
reported similar  data 131). 
The  results reported here were obtained by using mon- 
oclonal antibodies and rosetting  techniques  for cell frac- 
tionation. Normal B cells were isolated from peripheral 
blood non-T cells according  to the expression of sIg or of 
the B1 marker. B cell enrichment within the B1+ fraction 
proved by far superior  to that detected in sIg' cells, which 
contained  relevant  proportions of monocytes. In addition, 
B cell suspensions could be additionally purified by treat- 
ment with anti-monocyte monoclonal antibodies and 
complement. In theory, it cannot be excluded that  the 







separation  procedures used in  these experiments select 
a small  subset of slightly adherent, OKM1-, Fc receptor 
positive cells, which are highly efficient IL 1 producers 
and eo-purify with B cells through nonspecific binding of 
the B1 monoclonal antibody or of antibody coated ox 
erythrocytes.  Furthermore, Fc receptor interaction  with 
ox erythrocytes could deliver an effective signal  for cy- 
tokine release. However, it is unlikely that IL 1 production 
was  attributable  to  contaminant monocytes for the fol- 
lowing reasons: the high degree of purity for the  normal 
B cell fractions used: the finding that on a per cell basis, 
B cell-enriched suspensions were as  efficient IL 1 pro- 
ducers as autologous monocytes, and the observation 
that CLL B cells purified by negative selection methods 
(i.e.. removal of E rosetting cells followed by killing of 
residual non-B cells with monoclonal antibodies and 
complement) produced IL 1 in amounts comparable  with 
those of normal B cell suspensions. Nonetheless, because 
a small  contaminant of monocytes was still present in 
the B cell suspensions, the possibility that monocytes 
cooperate with B cells in inducing IL 1 release by the 
latter cells cannot  be  dismissed. 
We have not yet observed a relationship between IL 1 
production and  other  characteristics of the single B-CLL 
cases,  such as lymphocyte counts,  treatment,  duration, 
or  stage of disease. Previously we have  shown that indi- 
vidual B-CLL clones  reach  different  maturational  stages 
in vivo, which can be assessed  on  the  basis of the capacity 
of the cells to produce and secrete Ig molecules and of 
their  responsiveness  to growth and differentiation  fac- 
tors (32, 331. When these  parameters were used to deter- 
mine the  maturational  stages of the B-CLL cases studied, 
no  correlation was found between the degree of matura- 
tion of the malignant B cells and IL 1 production. Whether 
or not B-CLL cells that release IL 1 in vitro also produce 





80 100 120 140 160 180 
EFFLUENT VOLUME tml)  
ammonium sulphate precipitated, and precipitates were applied to a Sephadex G-75 column:  fractions were collected, and aliquots of each fraction 
Figure I .  Elution patterns of normal B cell-derived (-)or normal monocyte-derived (---) factors with IL 1 activity. Culture supernatants were 
were assayed for IL 1 activity. 
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tional  studies  on  serum  and  urine  (34) from these  patients 
are now in  progress. 
Several  explanations for the heterogeneity in IL 1 pro- 
duction by B-CLL cells can be considered. First, IL 1 
production could be  restricted  to  a B cell subset of which 
the lymphokine producing B-CLL cases represent the 
counterpart.  Second, IL 1 may be released at a  particular 
B cell maturational  stage that  cannot yet be defined  with 
the available  methods. Finally, all B-CLL cells could pro- 
duce IL 1,  but  in some cases,  this lymphokine could be 
absorbed  on the  malignant cells. This possibility is sug- 
gested by the following observations: IL 1 can  affect both 
proliferation and differentiation of B cells (35-40). and 
some Epstein Barr virus-infected B cell lines produce IL 
1, which can, at least  in part,  maintain  their proliferative 
capacity (41). 
The  demonstration that B cells release IL 1 is in  ac- 
cordance  with  their  capacity  to  present  antigens (17-25) 
and reinforces the view that B cells function as accessory 
cells for T cell proliferation.  Finally, in view of the role 
that IL 1 plays for the induction  and/or  maintainance of 
inflammatory  reaction (26). our  data suggest a novel B 
cell function  in  this  particular  feature of the response  to 
pathogens. In this  connection, it is of note that we have 
preliminarly  shown that both  normal and malignant B 
cells are  also capable of producing considerable amounts 
of granulocyte-macrophage colony stimulating  factor 
(Pistoia et al., manuscript  in  preparation). 
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